TICKERNERD
Menu
CORCORHealthcare · Medical Distribution

COR Stock Forecast: Cencora, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$308
−0.95% on the day

The 14 Wall Street analysts covering Cencora, Inc. hold a median 12-month price target of $350 — +13.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 1 Aug 2026 — in the lower half.

Market cap
$60.0B
Ticker Nerd rank
48 / 100
Median analyst target
$350
Analysts covering
14
Total return, dividends reinvested
1W
−0.9%
1M
+4.0%
YTD
−8.3%
1Y
+7.7%
From 52W high
−17.4%
From 52W low
+22.3%
$252
$373
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

COR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cencora, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Growth
79
Value
74
Quality
62
Momentum
54
Revisions
46
Issuance
42
Accruals
27
Size
4

Volatility (100): The share price has been relatively steady.

Accruals (27): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (4): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Cencora, Inc. — and when they’d sell — is the membership.

Wall Street

COR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on COR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$250$300$350$400Oct 25Jan 26Apr 26Jul 26CORHigh $412Median $350Low $310

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says14 analysts
12 Buy2 Hold0 Sell
Low $310Median $350High $412

The green dot is the last close — the median target sits +13.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 June 2026B of A SecuritiesMaintainsNeutral$280 → $285
10 June 2026BarclaysMaintainsOverweight—
11 May 2026Wells FargoMaintainsOverweight—
7 May 2026BairdMaintainsOutperform—
7 May 2026CitigroupMaintainsBuy—
7 May 2026Evercore ISI GroupMaintainsOutperform—
7 May 2026UBSMaintainsBuy—
28 Apr 2026William BlairInitiatesMarket Perform—
8 Apr 2026Evercore ISI GroupMaintainsOutperform—
13 Feb 2026BarclaysMaintainsOverweight—
10 Feb 2026JP MorganMaintainsOverweight—
10 Feb 2026Wells FargoMaintainsOverweight—
5 Feb 2026Evercore ISI GroupMaintainsOutperform—
29 Jan 2026Morgan StanleyUpgradeOverweight—
22 Jan 2026JefferiesUpgradeBuy—
5 Jan 2026B of A SecuritiesMaintainsNeutral—
9 Dec 2025BarclaysInitiatesOverweight—
11 Nov 2025JP MorganMaintainsOverweight—
11 Nov 2025Wells FargoMaintainsOverweight—
10 Nov 2025TD CowenMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

COR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.9%
Analysts raising
1
Analysts cutting
0
Fundamentals

Cencora, Inc. (COR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.6×

Cheaper than 34% of US stocks

Price / sales
0.2×

Cheaper than 93% of US stocks

Price / book
17.7×

Cheaper than 6% of US stocks

EV / EBITDA
13.9×

Cheaper than 26% of US stocks

Growth & margins
Revenue growth (YoY)
3.8%

Higher than 38% of US stocks

Earnings growth (YoY)
128.6%

Higher than 89% of US stocks

Gross margin
4.6%

Higher than 7% of US stocks

Operating margin
1.7%

Higher than 51% of US stocks

Net margin
0.8%

Higher than 48% of US stocks

Returns & dividend
Return on equity
107.1%

Higher than 96% of US stocks

Return on assets
3.5%

Higher than 69% of US stocks

Dividend yield
0.8%

Higher than 17% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

COR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Distribution
CompanyMarket capTKN rank
CORCencora, Inc.$60.0B
48
CAHCardinal Health, Inc.$54.7B
94
MCKMcKesson Corp.$100.2B
73
HSICHenry Schein, Inc.$9.8B
78
BSXBoston Scientific Corp.*$69.3B
63
MDLNMedline, Inc.*$51.6B
9
EWEdwards Lifesciences Corp.*$49.6B
86

* Nearest Healthcare names by size — few medical distribution companies of this scale trade in the US universe.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. COR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest COR news & analysis

Cencora to Report Q3 Earnings: Is a Beat Likely for the Stock?

Zacks Investment Research · 3 Aug 2026neutral

A Zacks Investment Research article previews Cencora's Q3 earnings, noting potential strength in specialty pharmaceuticals and oncology expansion alongside margin gains, while citing headwinds from pricing dynamics and GLP-1 trends.

Why it matters — COR watchers would care because the report outlines the key cross-currents — specialty pharma strength versus revenue pressures — that could shape the company's near-term financial results.

Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Zacks Investment Research · 31 July 2026neutral

Zacks Investment Research highlights that analysts are looking beyond standard revenue and EPS estimates for Cencora's Q3 2026 earnings, evaluating projections for key business metrics.

Why it matters — COR watchers would care because the article suggests deeper metric-level analysis may offer a more complete picture of the company's quarterly performance.

Cencora (COR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks Investment Research · 29 July 2026positive

Zacks Investment Research reported that Cencora (COR) has the right combination of key ingredients for a likely earnings beat in its upcoming quarterly report, and provided expectations for the release.

Why it matters — A COR watcher would care because the article suggests the company may deliver better-than-expected results in its next earnings report.

Here's Why You Should Add Cencora Stock to Your Portfolio Now

Zacks Investment Research · 24 July 2026positive

Zacks published a note on Cencora highlighting its specialty expansion, supply-chain investments and international momentum as growth drivers, while noting risks from pricing, debt and regulation.

Why it matters — COR watchers would care because the piece outlines both the company's growth catalysts and the key risks affecting its outlook.

FAQ

Frequently asked questions about COR stock

What is the COR stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Cencora, Inc. have a median 12-month price target of $350, with estimates ranging from $310 to $412. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is COR stock a buy right now?

Of the 14 analysts covering Cencora, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cencora, Inc. 48 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank COR?

As at 1 Aug 2026, Cencora, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will COR stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +13.5% from the last close, and Ticker Nerd's factor model ranks Cencora, Inc. 48 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the COR stock forecast for 2030?

No analyst covering Cencora, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for COR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $310 to $412 over the next 12 months.

How has COR stock performed over the past year?

Cencora, Inc. returned +7.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cencora, Inc. do?

Cencora, Inc. is a global pharmaceutical solutions organization that serves as a critical link between drug manufacturers, healthcare providers, pharmacies, and patients.

What is the latest news on COR?

The most recent item we track (Zacks Investment Research, 3 Aug 2026): "Cencora to Report Q3 Earnings: Is a Beat Likely for the Stock?". A Zacks Investment Research article previews Cencora's Q3 earnings, noting potential strength in specialty pharmaceuticals and oncology expansion alongside margin gains, while citing headwinds from pricing dynamics and GLP-1 trends.

Company

About Cencora, Inc.

Cencora, Inc. is a global pharmaceutical solutions organization that serves as a critical link between drug manufacturers, healthcare providers, pharmacies, and patients. Headquartered in Conshohocken, Pennsylvania, Cencora focuses on sourcing and distributing branded, generic, and specialty pharmaceutical products, along with over-the-counter healthcare items and related medical supplies. The company plays a central role in the healthcare supply chain by providing secure, reliable distribution and logistics services, as well as commercialization support for brand and specialty therapies. Beyond distribution, Cencora offers consulting, technology, analytics, and market access solutions designed to enhance provider efficiency and support patient access to complex treatments. Its operations span human and animal health, reflecting a broad presence across hospitals, health systems, community practices, specialty pharmacies, and veterinary channels. Today, Cencora is recognized as a leading partner for pharmaceutical innovators and healthcare organizations, helping ensure that therapies can reach the right patients in numerous markets worldwide.

CEO Dr. Robert P. Mauch Ph.D., PharmD · 47,000 employees · United States · https://www.cencora.com